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Abstract
Background: Determination of clot lysis times on whole blood, diluted whole blood, plasma or
plasma fraction has been used for many years to assess the overall activity of the fibrinolytic system.
We designed a completely computerised semi-automatic 8-channel device for measurement and
determination of fibrin clot lysis. The lysis time is evaluated by a mathematical analysis of the lysis
curve and the results are expressed in minute (range: 5 to 9999). We have used this new device
for Euglobulin Clot Lysis Time (ECLT) determination, which is the most common test used in
laboratories to estimate plasma fibrinolytic capacity.
Results: The correlation between ECLT and manual method is very tight : R = 0,99; p < 10-6. The
efficiency scores of the method are <4% in intra-assay and <7% in inter-assay. It allows to achieve
the tests on hyperlipaemic samples. This new device has been easily integrated in laboratory
routine and allows to achieve several ECLT every day without disturbance of laboratory workflow.
Conclusions: The routine use of this new device could be useful in various situations such as
assessment in atherosclerosis and arteriosclerosis associated diseases, coagulation survey of liver
transplantations, cardiovascular surgery or pharmacological research.
It has already provided highly promising results in preliminary studies on the relation between
fibrinolysis and cardiovascular risk factors.
Background
The fibrinolytic system is involved in many physiological
and pathophysiological processes. An increase in fibrino-
lytic activity may induce a bleeding tendency. More com-
monly, a reduced activity of the system is observed and
this may contribute to the pathogenesis of thromboem-
bolic diseases [1,2]. In earlier clinical studies, an impaired
fibrinolytic function had been reported in subjects suffer-
ing from venous thrombosis [3]. Newer studies have em-
phasised the importance of fibrinolytic disturbances in
the development of arterial disease and thrombosis [4,5].
These alterations were especially observed in patients with
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advanced atherosclerosis, when developing acute-coro-
nary syndrome or diabetes mellitus [6,7]. The fibrinolytic
abnormalities were also observed in hypertriglyceridemic
patients before developing atherosclerosis or vascular
complications [8]. Most of the tests used to measure the
blood fibrinolytic potential are not suitable for routine
clinical practices. Analysis of t-PA and PAI-1 considers two
isolated components of the fibrinolytic system. Further-
more, these tests have to be performed in series and so
cannot be done very frequently in laboratory routine for
logistic and economic reasons. The Dilute Blood Clot
Lysis Time is a very long and subjective procedure requir-
ing a continuous monitoring by an observer who has to
determine when the clot is lysed. The Euglobulin Clot
Lysis Time (ECLT) is the most commonly used test. It
seems to represent the interaction between the activity of
t-PA and PAI-1 [11] and allows to measure both baseline
and stimulated fibrin dissolution. Although this test is in-
expensive and adapted to single tests system, it is very dif-
ficult to promote in clinical practice, since it is long, and
require an observer to record the clot lysis.
We have designed a new semi-automatic method for clot
lysis measurement that includes several important im-
provements which are: 1) the device is operator independ-
ent during the analysis of the fibrinolysis process and for
the determination of the lysis time, 2) allows the analysis
of samples with a broad range of lysis time, 3) allows the
analysis of individual samples and is easily integrated in
the laboratory routine. To answer to these points, our new
system has been completely computerised. ECLT has been
chosen as first application. We have compared the effi-
ciency of ECLT with the new device to the classical manual
method and to a new test from Stago, the Global Fibrino-
lytic Capacity (GFC). In addition, the test was also per-
formed on high blood triglycerides level, to test the
optical sensitivity and robustness of our device.
Results
Efficiency scores of the semi-automatic method and com-
parison with the manual method
The variability of the complete semi-automatic procedure
was estimated from frozen plasma pool of the first 11 vol-
unteers, the mean lysis time averaging 300 min. The vari-
ation coefficients for B and C points were <4% in intra-
assay and < 7% in inter-assay, respectively (8 tests/day
over 10 different days). The relation between manual and
semi-automatic method is shown in Fig 3. For the B point
the curve equation of the correlation between both meth-
ods was y = -3.04 + 0.97.x (R = 0.99, p < 10-6). The corre-
lation appeared similar for the C point. The
corresponding curve equation was y = 2.62 + 1.01.x (R =
0.99, p < 10-6).
No statistically significant difference was found between
manual results, B or C point, before and after venous oc-
clusion conditions.
For the semi-automatic method, we have chosen arbitrar-
ily the B point from the lysis curve to determine the lysis
time Fig 2 and in addition, this point corresponds about
to the time value of lysis assessed in manual method.
Normal values are for men (n = 21), 208 min (range, 118–
303) and for premenopausal women (n = 25), 117 min
(range, 100–174) (p = 0.04).
Assay in hypertriglyceridemic condition
The increase of the blood triglycerides level induced a sof-
tening of amplitude of the signal (data not shown). This
softening did not affect the determination of the lysis time
by our device. However, for a direct observer, the variation
in turbidity induced by clot formation and lysis in hyper-
lipemic condition was very difficult to detect for triglycer-
ides above 300 mg/dl Fig 4.
Until 800 mg/dl of triglycerides, the semi-automatic sys-
tem has always achieved an appropriate analysis of the
curve.
Relation between the ECLT and Global Fibrinolytic Capac-
ity
For basal and stimulation states, the relationship between
the two tests is better described by an inverse exponential
curve y = 54.31 e-0.008x, R2 = 0.71, independently of the
stimulation state or the way to achieve Fig 5.
When the ECLT was lower than 200 minutes, we observed
a fair correlation between both tests (R2 = 0.55). For ECLT
> 300 min, DD generation in GFC is suppressed.
Table 1 shows the results of ECLT and GFC of different
groups in basal and stimulate conditions.
Both tests were identically sensitive to fibrinogen level,
since the fibrinogen level arises, the fibrinolytic capacity
decreased Fig 6.
Discussion
Our aim was to create a device which allowed to reintro-
duce the fibrinolysis measurement in routine practice
without disturbing the laboratory workflow, in this work
we chose ECLT. An optical computerised system for the
follow-up of fibrinolysis process and for determination of
lysis time made the test autonomous and allowed further
developments. With our device, we obtained a very tight
correlation with the manual method, but this one has
been made in condition unachievable in routine. The re-BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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sponse to venous occlusion were identical for manual and
semi-automatic method.
We have obtained a significant difference between normal
values in men and premenopausal women in accordance
to the notion that women have a better fibrinolytic capac-
ity than men [15].
Another procedure, allowing quantitative ECLT assess-
ment with a microtiter plate reader, was reported by
Urano et al [11]. It provided reliable and reproducible da-
ta, with the lysis time determined as the half lysis point
obtained by calculation of the midpoint between maxi-
mum and minimum points of turbidity. However, the tur-
bidity of the clot was only measured every 30 minutes by
the microtiter plate reader. We used a higher sampling rate
of the recorder, i.e. every one minute. Our mathematical
analysis theoretically allows a better accuracy since it is
based on much more discrete measurements than in the
system of Urano using only an unique half lysis point.
Moreover, our device allows to analyse up to 8 samples in-
dividually and to measure the lysis time over a broad
range (5 minutes to 9999 minutes) strictly stabilized at
37°C. The mathematical analysis determines not only the
critical points (A, B, C) of the lysis curve, but will also en-
able to explore the kinetics of fibrin clot degradation in
the future.
Finally, this device is able to determine the lysis time in
hyperlipemic condition. The GFC from Stago can also be
applied on single samples. This test evaluates the fibrino-
Figure 1
Outline of the new device for ECLT measurement.BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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lytic process by the generation of D-Dimer from an exter-
nal and standardized fibrin clot. It is rather expensive due
to the reagent itself and the cost of DD evaluation. At first
sight, we thought that the fibrinogen level had no effect
on GFC and that this test could result in a different infor-
mation than ECLT. But, both tests are surprisingly, equally
sensitive to patient's fibrinogen level. Fibrinogen can indi-
rectly or directly interfere with fibrinolysis process. The
first mechanism may be common to both tests, the fibrin-
ogen level can represent chronic inflammation which may
impaire fibrinolytic balance [16].
The second mechanism (direct effect) is probably differ-
ent for ECLT than for GFC. For ECLT, the density of fibrin
clot is in relation with fibrinogen level and this density
may also modulates lysis time [17]. For GFC, a constant
amount of t-PA is added in plasma sample which is placed
at the surface of a standardised fibrin clot (the reaction is
stopped after one hour). A previous study [18] reported
that t-PA incubated with plasma in presence of a fibrin
clot induced fibrinogen proteolysis. The authors conclud-
ed, that the products of t-PA-induced degradation of
cross-linked fibrin could potentiate t-PA-mediated fibrin-
ogenolysis by providing a surface for t-PA and plasmino-
gen binding thereby promoting plasmin generation. This
plasmin is a more important mediator of fibrinogenolysis
than plasmin generated on the clot surface. We suppose
that, a part of plasma plasminogen is less available for the
standardised fibrin clot degradation and that this phe-
nomenon can induce a decrease of D-Dimer generated
during the test.
The GFC shows a weak sensitivity in hypofibrinolytic pa-
tients with no possibility to distinguish between two dif-
ferent samples or to measure a first slight response to a
treatment. Alternative protocols should be designed to al-
low an evaluation of these samples. Several tests on plas-
ma were achieved on samples providing from venous
occlusion and hepatic transplantation (data not shown).
The device determine easily the lysis time on plasma.
However, in basal condition fibrinolysis is too slow. Dif-
ferent preparations of reagents are in development, to re-
duce lysis time, for the new applications with our device.
Figure 2
The lines represent the complete fibrinolysis process including formation, latency and dissolution of the fibrin
clot, the first and second derivative. All points (A,B,C) are expressed in seconds, minutes and hours. The A point repre-
sents the peak time of fibrin clot formation, B point, the peak to fibrin clot lysis, and C point, the end of the complete fibrinol-
ysis process.BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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The new apparatus is an important tool for studying fibri-
nolysis in-vitro, moreover, it can reintroduce lysis time in
routine for a better approach of hypofibrinolysis.
It has allowed us to achieve preliminary studies on the ef-
fect of lipids level on ECLT in men and women [19] and
the relations between the classical cardiovascular risk fac-
tors and ECLT [20].
Conclusion
In conclusion, we observed a good correlation between
the measurement of lysis time by the manual method and
the new device. This new evaluation of the ECLT is more
objective. The results are highly reproducible and the test
easy to perform. The reagents and disposable are not ex-
pensive (micro-cuvets, acetic acid, Owren solution and
thrombin). At the moment, it is integrated in our labora-
tory routine practice for extended evaluation.
Figure 3
Correlation between the manual method and the semi-automatic method. ECLT by the semi-automatic method is
determined by the B point. The plots represent the lysis time of the 11 volunteers before and after venous occlusion. The
equation is calculated on the 24 points.BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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This ECLT test should be reintegrated in clinical routine,
and could be conveniently added to the panel of estimates
of biological risk factors for atherothrombosis. Moreover,
this device is not limited to ECLT, it could be used with
different sample preparations.
Materials and methods
Population data
The normal values in non-stimulated condition were ob-
tained from 25 women and 21 men. Men were of 49 years
old (range, 32–54) and women 44 years old (range, 31–
48) (p = 0.3). Volunteers were free from any clinical signs
of peripheral arterial disease, diabetes mellitus, arterial
hypertension, history of cardiovascular disease, inflam-
matory syndrome and smoking habit. They were also free
of medication and women were in premenopausal status.
For correlation with the manual method, blood samples
from others 11 fasting volunteers from laboratory were
obtained before and after a 10 minutes venous occlusion.
The relation with the Global Fibrinolytic Capacity (GFC)
was established on 42 samples obtained from patients ex-
plored for thromboembolic disorders. Among these, 25
gave another sample after a 10 minutes venous occlusion.
The stimulation conditions were also evaluated on pa-
tients, taken 0.5 hour, 1 or 2 hours after desmopressin in-
fusion (therapeutic challenge) in mild haemophilia A and
von Willebrand patients.
Figure 4
Optical evolution of the turbidity of the euglobulin fraction during the fibrinolysis process. D.Turb: Delta turbidity
represents the variation of the signal compared to the start value of the process. Delta turbidity is expressed in arbitrary units.
Pre/Post prandial : Total Cholesterol: 319/304 mg%, Triglycerides: 144/385 mg%.BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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Blood sampling
For the normal values, blood samples from antecubital
vein were obtained between 08:00 and 09:30 a.m. Sam-
ples were harvested in 0.13 M-citrated vacuum tubes
(Venoject® Terumo) and immediately put into melting
ice. After centrifugation at 4000 g for 10 min at 4°C, the
plasma samples were stored at -80°C until analysis. The
tests were performed either immediately or on frozen/
thawed samples (-80°C). Fibrinogen level was tested on
STA® apparatus according to manufacturer's instructions.
Euglobulin fraction preparation
300 µl of acetic acid (0.25%) and 3.6 ml of desionized wa-
ter were added to 400 µl plasma (final pH ≅  5.9). The sam-
ple was then put into melting ice during 20 min and
centrifuged at 4000 g for 10 min at 4°C. The supernatant
was discarded and the pellet was resuspended in 400 µl of
Owren-Koller buffer (DIAGNOSTICA STAGO®,  France).
The clot formation started when 100 µl of thrombin (1.75
U/ml, DIAGNOSTICA STAGO®, France) were added.
ECLT measurement: conventional manual method
The euglobulin activated fraction was put at 37°C in a
thermostatic bath and the clot was carefully examined
every 5 minutes by the operator who was continously
present during the measurement. Lysis was considered
complete when the clot was no more apparent (end time
point expressed in min).
Figure 5
Correlation between the plasma fibrinolytic capacity evaluated by GFC and the ECLT achieved by the semi-
automatic method. First group at basal (red) and post venous occlusion (blue) (n = 25). Second group with Desmopresin
stimulation [n = 17, basal condition (red), DDAVP 30 min, DDAVP 60 min, DDAVP 120 min (green)].
Table 1: Values of ECLT and GFC in different groups.
ECLT (min) GFC D-Dimer (µg/ml)
Group 1 (n = 25)
Basal condition 264 (165–482) 20.3 (1.1–26.7)
Post venous occlusion 56 (26–167) 23.7 (1.1–41.7
Group 2 (n = 17)
DDAVP (basal condition) 181 (108–249) 20.6 (7.6–31.3)
DDAVP (30 min) 35 (25–53) 39 (30.4–46)
DDAVP (60 min) 61 (45–98) 42.13 (26–45)
DDAVP (120 min) 107 (76–246) 27 (12.1–38.7)
Median (25% – 75%)BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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Semi-automatic ECLT measurement
The procedure is very easy, the sample (euglobulin frac-
tion, plasma or others) is introduced in a microcuvette
and put in the apparatus, in a well. Then, the operator fol-
lows three operations to start the tests: 1- identification of
sample, 2- add thrombin, 3- push on set button to start
the recording of fibrinolysis process.
The new device composition was designed as Figure 1:
- a thermostatic bloc (37°c) with eight photometric meas-
ure channels.
- a programmable language control (PLC).
- a computer and a software for the mathematical analysis
of the fibrinolysis process.
Thermostatic bloc
the bloc is made of pure aluminium (360 ×  30 ×  100 mm)
and is warmed by two resistances of 20 W. It is designed
to insert spectrophotometric micro-cuvets (10 ×  4 ×  45
mm Sarstedt®) into 8 wells. Each well includes one emitter
(diode: SFH 409) and one receptor (phototransistor:
SFH309FA), both operating at 890 nm. When the clot is
formed, the phototransistor signal decreases reflecting a
Tyndall effect [12].
Programmable Language Control
ED&A V10, Antwerpen, Belgium. The sensors are connected
to the PLC which transforms the analogic data (0–10 V)
into digital data (12 bits). The data are transmitted to the
computer by RS232.
Data analysis
The computer records every one minute the data from
each channel. The software (developed with Windev® 4.1,
France) generates the graph of the fibrinolytic process. At
the end, the curve graph is analysed with a mathematical
algorithm. The first and second derivatives are computed
by a convolution matrix13. These calculations aim at de-
termining the peak time to clot formation (A point, first
derivative), the peak time to clot lysis (B point, first deriv-
ative), and the end of the complete fibrinolysis process (C
point, when the first and the second derivatives are under
the background ≅  0). Later, other parameters should also
be considered. The design of a lysis curve is exemplified in
Figure 2. The x-axis/y-axis respectively represent time and
evolution of the signal sensor. Mathematical analysis or
complete procedure can be started individually for each
sample and at every moment without disturbing the
measurements of other samples. The final assembly was
performed by EREM, (Marcinelle, Belgium) and the sys-
tem is distributed since 2001 by BIOK, (Montigny-Le-Til-
leul, Belgium).
Figure 6
Correlation between the patient fibrinogen levels from the two groups, and the fibrinolytic capacity evaluated by Euglobulin
Clot Lysis Time and Global Fibrinolytic Capacity, in basal condition (n = 42).BMC Biotechnology 2002, 2 http://www.biomedcentral.com/1472-6750/2/8
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The Global Fibrinolytic Capacity (Stago, France)
This test estimates the fibrinolytic activity in plasma
through the measurement of generated D-Dimer from a
standardized fibrin amount in presence of a constant
amount of exogenous t-PA and by contact phase activators
[14]. The test was performed according to manufacturer's
instructions and the results were expressed as generated
DD (µg/ml).
Test of hypertriglyceridemic status
To assess the blood triglycerides effect on the optical prop-
erty of the euglobulin fraction, two samples were ob-
tained from one hyperlipemic volunteer in preprandial
and 2 hours postprandial states. The ECLT was examined
on both samples with a photographic follow up. The total
cholesterol and the triglycerides were determined by rou-
tine laboratory methods, on a Synchron LX20 (Beck-
man®).
Statistical analysis
SigmaStat® Jandle Scientific software was used. Non para-
metric statistical analysis with Spearman test for the corre-
lations and Mann-Whitney test for the comparison
between men and women were used. The relation be-
tween the GFC and the semi-automatic method was de-
scribed by an exponential equation. Data are presented as
median values and ranges (25%–75%). A p value < 0.05
was considered as statistically significant.
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